LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

LLY

1,003.75

-0.1%↓

JNJ

245.32

-0.54%↓

ABBV

235.99

+1.04%↑

NVS

165.01

+0.53%↑

AZN

201.13

+0.17%↑

Home・Akciju saraksts・Innoviva Inc

Innoviva Inc

Slēgts

SektorsVeselības aprūpe

22.67 1.75

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

Max

22.91

Galvenie mērījumi
By Trading Economics
Ienākumi	152M 242M
Pārdošana	10M 118M
P/E Sektora vidējais	13.374 66.845
Peļņas marža	204.74
Darbinieki	127
EBITDA	100M 208M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+62.07% upside

Dividendes
By Dow Jones
Nākamie ieņēmumi	2026. g. 5. maijs

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	519M 1.7B
Iepriekšējā atvēršanas cena	20.92
Iepriekšējā slēgšanas cena	22.67

Ziņu noskaņojums

By Acuity

87%

13%

331 / 352 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

18.57 / 18.75 Atbalsts un pretestība

Innoviva Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2026. g. 3. marts 18:43 UTC

Galvenie ziņu notikumi

Fed's Kashkari Says Too Soon To Know Inflation Impact From Middle East Conflict

2026. g. 3. marts 17:33 UTC

Iegādes, apvienošanās, pārņemšana

Ziff Davis to Sell Connectivity Division to Accenture for $1.2 Billion -- Update

2026. g. 3. marts 23:45 UTC

Tirgus saruna

Nikkei May Fall on Continued Concerns About Energy Costs -- Market Talk

2026. g. 3. marts 23:44 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold Rises on Possible Dip-Buying Amid Ongoing Middle East Conflict -- Market Talk

2026. g. 3. marts 23:25 UTC

Tirgus saruna

Bannerman Energy Likely to Raise Less Equity for Uranium Projects -- Market Talk

2026. g. 3. marts 23:25 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2026. g. 3. marts 22:38 UTC

Galvenie ziņu notikumi

Iran Conflict Pushes Europe Toward Fresh Energy Crisis -- WSJ

2026. g. 3. marts 22:16 UTC

Peļņas

Berkshire Provides Scant Fourth-Quarter Financials. Investors Need to Do Their Own Calculations. -- Barrons.com

2026. g. 3. marts 22:09 UTC

Peļņas

Century Aluminum Changed Historical Method of Proportionately Consolidating Jamalco Production Assets to a Full Consolidation

2026. g. 3. marts 22:06 UTC

Peļņas

Century Aluminum: Accounting Change for 2023 and 2024 Doesn't Impact Net Income Attributable to Century Stockholders

2026. g. 3. marts 22:05 UTC

Peļņas

Century Aluminum Initially Concluded That an Accounting Change Was Immaterial, SEC Staff Disagreed With Company's Materiality Conclusion

2026. g. 3. marts 22:03 UTC

Peļņas

Century Aluminum to Restate Certain Results in Connection Wtih Accounting Change for Jamalco

2026. g. 3. marts 21:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Tech, Media & Telecom Roundup: Market Talk

2026. g. 3. marts 21:50 UTC

Tirgus saruna

Galvenie ziņu notikumi

Basic Materials Roundup: Market Talk

2026. g. 3. marts 21:45 UTC

Galvenie ziņu notikumi

The Iran War Puts the Fed's Rate-Cut Timeline in Doubt -- Barrons.com

2026. g. 3. marts 21:37 UTC

Peļņas

EVgo Stock Rises as Earnings Defy EV Slump. The Rest of 2026 Doesn't Look So Rosy. -- Barrons.com

2026. g. 3. marts 21:26 UTC

Galvenie ziņu notikumi

Freeport McMoRan Stock Slides as the Mideast Conflict Hits Commodities -- Barrons.com

2026. g. 3. marts 20:31 UTC

Tirgus saruna

Galvenie ziņu notikumi

U.S. Natural Gas Gains on Middle East Turmoil, Weather Outlook -- Market Talk

2026. g. 3. marts 20:04 UTC

Tirgus saruna

Galvenie ziņu notikumi

Oil Futures Pull Back as Trump Offers Shipping Protection -- Market Talk

2026. g. 3. marts 19:17 UTC

Tirgus saruna

Galvenie ziņu notikumi

Gold and Silver Drop as Energy Surges -- Market Talk

2026. g. 3. marts 18:43 UTC

Peļņas

Berkshire CEO Abel Is Fond of Financial Metric Similar to One Criticized by Buffett -- Barrons.com

2026. g. 3. marts 18:29 UTC

Tirgus saruna

Galvenie ziņu notikumi

Global Energy Roundup: Market Talk

2026. g. 3. marts 18:29 UTC

Tirgus saruna

Galvenie ziņu notikumi

Norsk Hydro Announces Stoppage of Qatar Aluminum Smelter -- Market Talk

2026. g. 3. marts 18:22 UTC

Galvenie ziņu notikumi

Fed's Kashkari on March Projections: Had a Lot of Confidence Up Until a Few Days Ago

2026. g. 3. marts 18:22 UTC

Galvenie ziņu notikumi

Fed's Kashkari: Too Soon to Know Impact Iran Conflict Will Have on Inflation

2026. g. 3. marts 18:17 UTC

Tirgus saruna

Galvenie ziņu notikumi

Strait of Hormuz Standstill Keeps Bid in Oil Futures -- Market Talk

2026. g. 3. marts 18:14 UTC

Peļņas

How Long Can Anthropic Play Defense? -- WSJ

2026. g. 3. marts 17:41 UTC

Galvenie ziņu notikumi

Exxon Is Down Since the Iran Conflict. These Energy Stocks Are Bigger Winners. -- Barrons.com

2026. g. 3. marts 17:36 UTC

Galvenie ziņu notikumi

Iran Conflict is Starting to Boost Gasoline Prices -- Update

2026. g. 3. marts 17:28 UTC

Iegādes, apvienošanās, pārņemšana

Tinicum, Blackstone to Make Decision on Offer By End of Day March 31

Salīdzinājums

Cenas izmaiņa

Innoviva Inc Prognoze

Cenas mērķis

By TipRanks

62.07% augšup

Prognoze 12 mēnešiem

Vidējais 37 USD 62.07%

Augstākais 46 USD

Zemākais 32 USD

Pamatojoties uz 4 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Innoviva Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

4 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 4 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam Innoviva Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

18.57 / 18.75Atbalsts un pretestība

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Noskaņojums

By Acuity

331 / 352 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.